nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Endophthalmitis—Pravastatin—atherosclerosis	0.0161	0.0242	CcSEcCtD
Apraclonidine—Upset stomach—Lovastatin—atherosclerosis	0.0138	0.0208	CcSEcCtD
Apraclonidine—Upset stomach—Simvastatin—atherosclerosis	0.0129	0.0195	CcSEcCtD
Apraclonidine—Eye irritation—Lovastatin—atherosclerosis	0.0106	0.016	CcSEcCtD
Apraclonidine—Inflammation—Ezetimibe—atherosclerosis	0.00914	0.0138	CcSEcCtD
Apraclonidine—Inflammation—Simvastatin—atherosclerosis	0.00872	0.0131	CcSEcCtD
Apraclonidine—Dermatitis contact—Niacin—atherosclerosis	0.00768	0.0116	CcSEcCtD
Apraclonidine—Abnormal vision—Niacin—atherosclerosis	0.00677	0.0102	CcSEcCtD
Apraclonidine—Nasopharyngitis—Ezetimibe—atherosclerosis	0.00576	0.00868	CcSEcCtD
Apraclonidine—Disturbance in sexual arousal—Niacin—atherosclerosis	0.00559	0.00843	CcSEcCtD
Apraclonidine—Face oedema—Niacin—atherosclerosis	0.00544	0.00821	CcSEcCtD
Apraclonidine—Abdominal discomfort—Lovastatin—atherosclerosis	0.00544	0.0082	CcSEcCtD
Apraclonidine—Rhinitis—Rosuvastatin—atherosclerosis	0.00537	0.0081	CcSEcCtD
Apraclonidine—Pharyngitis—Rosuvastatin—atherosclerosis	0.00532	0.00802	CcSEcCtD
Apraclonidine—Abdominal discomfort—Simvastatin—atherosclerosis	0.00509	0.00767	CcSEcCtD
Apraclonidine—Nasopharyngitis—Pravastatin—atherosclerosis	0.00496	0.00748	CcSEcCtD
Apraclonidine—Infestation NOS—Ezetimibe—atherosclerosis	0.00496	0.00748	CcSEcCtD
Apraclonidine—Infestation—Ezetimibe—atherosclerosis	0.00496	0.00748	CcSEcCtD
Apraclonidine—Arrhythmia—Rosuvastatin—atherosclerosis	0.00479	0.00722	CcSEcCtD
Apraclonidine—Mental disorder—Rosuvastatin—atherosclerosis	0.0047	0.00708	CcSEcCtD
Apraclonidine—Pharyngitis—Ezetimibe—atherosclerosis	0.00442	0.00667	CcSEcCtD
Apraclonidine—Oedema peripheral—Ezetimibe—atherosclerosis	0.00439	0.00662	CcSEcCtD
Apraclonidine—Angiopathy—Ezetimibe—atherosclerosis	0.00404	0.00609	CcSEcCtD
Apraclonidine—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00401	0.00605	CcSEcCtD
Apraclonidine—Myalgia—Rosuvastatin—atherosclerosis	0.00397	0.00599	CcSEcCtD
Apraclonidine—Rhinitis—Niacin—atherosclerosis	0.00391	0.0059	CcSEcCtD
Apraclonidine—Mental disorder—Ezetimibe—atherosclerosis	0.0039	0.00588	CcSEcCtD
Apraclonidine—Haemorrhage—Niacin—atherosclerosis	0.0039	0.00588	CcSEcCtD
Apraclonidine—Erythema—Ezetimibe—atherosclerosis	0.00388	0.00585	CcSEcCtD
Apraclonidine—Dysgeusia—Lovastatin—atherosclerosis	0.00387	0.00584	CcSEcCtD
Apraclonidine—Rhinitis—Pravastatin—atherosclerosis	0.00385	0.0058	CcSEcCtD
Apraclonidine—Oedema peripheral—Niacin—atherosclerosis	0.00384	0.00579	CcSEcCtD
Apraclonidine—Pharyngitis—Pravastatin—atherosclerosis	0.00381	0.00575	CcSEcCtD
Apraclonidine—Infection—Rosuvastatin—atherosclerosis	0.00378	0.0057	CcSEcCtD
Apraclonidine—Visual impairment—Niacin—atherosclerosis	0.00376	0.00567	CcSEcCtD
Apraclonidine—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00373	0.00563	CcSEcCtD
Apraclonidine—Vision blurred—Lovastatin—atherosclerosis	0.00373	0.00562	CcSEcCtD
Apraclonidine—Mental disorder—Simvastatin—atherosclerosis	0.00372	0.00561	CcSEcCtD
Apraclonidine—Visual impairment—Pravastatin—atherosclerosis	0.0037	0.00558	CcSEcCtD
Apraclonidine—Erythema—Simvastatin—atherosclerosis	0.0037	0.00558	CcSEcCtD
Apraclonidine—Ill-defined disorder—Lovastatin—atherosclerosis	0.00367	0.00553	CcSEcCtD
Apraclonidine—Eye disorder—Niacin—atherosclerosis	0.00365	0.0055	CcSEcCtD
Apraclonidine—Dysgeusia—Simvastatin—atherosclerosis	0.00362	0.00546	CcSEcCtD
Apraclonidine—Ill-defined disorder—Ezetimibe—atherosclerosis	0.0036	0.00542	CcSEcCtD
Apraclonidine—Malaise—Lovastatin—atherosclerosis	0.00357	0.00538	CcSEcCtD
Apraclonidine—Angiopathy—Niacin—atherosclerosis	0.00354	0.00534	CcSEcCtD
Apraclonidine—Malaise—Ezetimibe—atherosclerosis	0.0035	0.00527	CcSEcCtD
Apraclonidine—Vision blurred—Simvastatin—atherosclerosis	0.00349	0.00525	CcSEcCtD
Apraclonidine—Arrhythmia—Niacin—atherosclerosis	0.00348	0.00525	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00347	0.00523	CcSEcCtD
Apraclonidine—Insomnia—Rosuvastatin—atherosclerosis	0.00344	0.00519	CcSEcCtD
Apraclonidine—Ill-defined disorder—Simvastatin—atherosclerosis	0.00343	0.00517	CcSEcCtD
Apraclonidine—Arrhythmia—Pravastatin—atherosclerosis	0.00343	0.00517	CcSEcCtD
Apraclonidine—Palpitations—Ezetimibe—atherosclerosis	0.00343	0.00517	CcSEcCtD
Apraclonidine—Paraesthesia—Rosuvastatin—atherosclerosis	0.00342	0.00515	CcSEcCtD
Apraclonidine—Erythema—Niacin—atherosclerosis	0.0034	0.00512	CcSEcCtD
Apraclonidine—Chest pain—Lovastatin—atherosclerosis	0.00337	0.00507	CcSEcCtD
Apraclonidine—Myalgia—Lovastatin—atherosclerosis	0.00337	0.00507	CcSEcCtD
Apraclonidine—Malaise—Simvastatin—atherosclerosis	0.00333	0.00503	CcSEcCtD
Apraclonidine—Tension—Niacin—atherosclerosis	0.00333	0.00502	CcSEcCtD
Apraclonidine—Discomfort—Lovastatin—atherosclerosis	0.00333	0.00501	CcSEcCtD
Apraclonidine—Chest pain—Ezetimibe—atherosclerosis	0.0033	0.00498	CcSEcCtD
Apraclonidine—Myalgia—Ezetimibe—atherosclerosis	0.0033	0.00498	CcSEcCtD
Apraclonidine—Nervousness—Niacin—atherosclerosis	0.0033	0.00497	CcSEcCtD
Apraclonidine—Dry mouth—Lovastatin—atherosclerosis	0.00329	0.00496	CcSEcCtD
Apraclonidine—Tension—Pravastatin—atherosclerosis	0.00328	0.00495	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00328	0.00494	CcSEcCtD
Apraclonidine—Dysgeusia—Pravastatin—atherosclerosis	0.00327	0.00494	CcSEcCtD
Apraclonidine—Discomfort—Ezetimibe—atherosclerosis	0.00326	0.00492	CcSEcCtD
Apraclonidine—Pain—Rosuvastatin—atherosclerosis	0.00326	0.00491	CcSEcCtD
Apraclonidine—Constipation—Rosuvastatin—atherosclerosis	0.00326	0.00491	CcSEcCtD
Apraclonidine—Nervousness—Pravastatin—atherosclerosis	0.00325	0.0049	CcSEcCtD
Apraclonidine—Dry mouth—Ezetimibe—atherosclerosis	0.00323	0.00487	CcSEcCtD
Apraclonidine—Infection—Lovastatin—atherosclerosis	0.00321	0.00483	CcSEcCtD
Apraclonidine—Vision blurred—Niacin—atherosclerosis	0.0032	0.00482	CcSEcCtD
Apraclonidine—Vision blurred—Pravastatin—atherosclerosis	0.00315	0.00475	CcSEcCtD
Apraclonidine—Chest pain—Simvastatin—atherosclerosis	0.00315	0.00475	CcSEcCtD
Apraclonidine—Myalgia—Simvastatin—atherosclerosis	0.00315	0.00475	CcSEcCtD
Apraclonidine—Infection—Ezetimibe—atherosclerosis	0.00314	0.00474	CcSEcCtD
Apraclonidine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00314	0.00473	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00311	0.00469	CcSEcCtD
Apraclonidine—Discomfort—Simvastatin—atherosclerosis	0.00311	0.00469	CcSEcCtD
Apraclonidine—Nervous system disorder—Ezetimibe—atherosclerosis	0.0031	0.00468	CcSEcCtD
Apraclonidine—Ill-defined disorder—Pravastatin—atherosclerosis	0.0031	0.00468	CcSEcCtD
Apraclonidine—Skin disorder—Ezetimibe—atherosclerosis	0.00307	0.00463	CcSEcCtD
Apraclonidine—Syncope—Niacin—atherosclerosis	0.00305	0.00459	CcSEcCtD
Apraclonidine—Oedema—Simvastatin—atherosclerosis	0.00302	0.00455	CcSEcCtD
Apraclonidine—Malaise—Pravastatin—atherosclerosis	0.00301	0.00455	CcSEcCtD
Apraclonidine—Abdominal pain—Rosuvastatin—atherosclerosis	0.00301	0.00454	CcSEcCtD
Apraclonidine—Palpitations—Niacin—atherosclerosis	0.003	0.00452	CcSEcCtD
Apraclonidine—Infection—Simvastatin—atherosclerosis	0.003	0.00452	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00294	0.00443	CcSEcCtD
Apraclonidine—Insomnia—Lovastatin—atherosclerosis	0.00292	0.0044	CcSEcCtD
Apraclonidine—Paraesthesia—Lovastatin—atherosclerosis	0.0029	0.00437	CcSEcCtD
Apraclonidine—Myalgia—Niacin—atherosclerosis	0.00289	0.00436	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00288	0.00435	CcSEcCtD
Apraclonidine—Dyspnoea—Lovastatin—atherosclerosis	0.00288	0.00434	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00287	0.00433	CcSEcCtD
Apraclonidine—Insomnia—Ezetimibe—atherosclerosis	0.00286	0.00432	CcSEcCtD
Apraclonidine—Myalgia—Pravastatin—atherosclerosis	0.00285	0.00429	CcSEcCtD
Apraclonidine—Chest pain—Pravastatin—atherosclerosis	0.00285	0.00429	CcSEcCtD
Apraclonidine—Paraesthesia—Ezetimibe—atherosclerosis	0.00284	0.00428	CcSEcCtD
Apraclonidine—Dry mouth—Niacin—atherosclerosis	0.00283	0.00426	CcSEcCtD
Apraclonidine—Dyspnoea—Ezetimibe—atherosclerosis	0.00282	0.00425	CcSEcCtD
Apraclonidine—Discomfort—Pravastatin—atherosclerosis	0.00281	0.00424	CcSEcCtD
Apraclonidine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00281	0.00423	CcSEcCtD
Apraclonidine—Fatigue—Lovastatin—atherosclerosis	0.00278	0.00419	CcSEcCtD
Apraclonidine—Oedema—Niacin—atherosclerosis	0.00277	0.00418	CcSEcCtD
Apraclonidine—Pain—Lovastatin—atherosclerosis	0.00276	0.00416	CcSEcCtD
Apraclonidine—Constipation—Lovastatin—atherosclerosis	0.00276	0.00416	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00275	0.00415	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00273	0.00412	CcSEcCtD
Apraclonidine—Asthenia—Rosuvastatin—atherosclerosis	0.00273	0.00412	CcSEcCtD
Apraclonidine—Insomnia—Simvastatin—atherosclerosis	0.00273	0.00412	CcSEcCtD
Apraclonidine—Oedema—Pravastatin—atherosclerosis	0.00273	0.00411	CcSEcCtD
Apraclonidine—Fatigue—Ezetimibe—atherosclerosis	0.00273	0.00411	CcSEcCtD
Apraclonidine—Infection—Pravastatin—atherosclerosis	0.00271	0.00409	CcSEcCtD
Apraclonidine—Paraesthesia—Simvastatin—atherosclerosis	0.00271	0.00409	CcSEcCtD
Apraclonidine—Pain—Ezetimibe—atherosclerosis	0.00271	0.00408	CcSEcCtD
Apraclonidine—Constipation—Ezetimibe—atherosclerosis	0.00271	0.00408	CcSEcCtD
Apraclonidine—Pruritus—Rosuvastatin—atherosclerosis	0.00269	0.00406	CcSEcCtD
Apraclonidine—Skin disorder—Niacin—atherosclerosis	0.00269	0.00406	CcSEcCtD
Apraclonidine—Dyspnoea—Simvastatin—atherosclerosis	0.00269	0.00406	CcSEcCtD
Apraclonidine—Feeling abnormal—Lovastatin—atherosclerosis	0.00266	0.00401	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00264	0.00398	CcSEcCtD
Apraclonidine—Feeling abnormal—Ezetimibe—atherosclerosis	0.00261	0.00393	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00261	0.00393	CcSEcCtD
Apraclonidine—Diarrhoea—Rosuvastatin—atherosclerosis	0.00261	0.00393	CcSEcCtD
Apraclonidine—Fatigue—Simvastatin—atherosclerosis	0.0026	0.00392	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00259	0.0039	CcSEcCtD
Apraclonidine—Pain—Simvastatin—atherosclerosis	0.00258	0.00389	CcSEcCtD
Apraclonidine—Constipation—Simvastatin—atherosclerosis	0.00258	0.00389	CcSEcCtD
Apraclonidine—Abdominal pain—Lovastatin—atherosclerosis	0.00255	0.00385	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00252	0.00381	CcSEcCtD
Apraclonidine—Dizziness—Rosuvastatin—atherosclerosis	0.00252	0.0038	CcSEcCtD
Apraclonidine—Insomnia—Niacin—atherosclerosis	0.00251	0.00378	CcSEcCtD
Apraclonidine—Abdominal pain—Ezetimibe—atherosclerosis	0.0025	0.00377	CcSEcCtD
Apraclonidine—Paraesthesia—Niacin—atherosclerosis	0.00249	0.00375	CcSEcCtD
Apraclonidine—Feeling abnormal—Simvastatin—atherosclerosis	0.00249	0.00375	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00249	0.00375	CcSEcCtD
Apraclonidine—Dyspnoea—Niacin—atherosclerosis	0.00247	0.00372	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00247	0.00372	CcSEcCtD
Apraclonidine—Insomnia—Pravastatin—atherosclerosis	0.00247	0.00372	CcSEcCtD
Apraclonidine—Somnolence—Niacin—atherosclerosis	0.00246	0.00371	CcSEcCtD
Apraclonidine—Paraesthesia—Pravastatin—atherosclerosis	0.00245	0.00369	CcSEcCtD
Apraclonidine—Dyspnoea—Pravastatin—atherosclerosis	0.00243	0.00367	CcSEcCtD
Apraclonidine—Dermatitis—Rosuvastatin—atherosclerosis	0.0024	0.00362	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Niacin—atherosclerosis	0.00239	0.00361	CcSEcCtD
Apraclonidine—Abdominal pain—Simvastatin—atherosclerosis	0.00239	0.0036	CcSEcCtD
Apraclonidine—Headache—Rosuvastatin—atherosclerosis	0.00239	0.0036	CcSEcCtD
Apraclonidine—Hypersensitivity—Lovastatin—atherosclerosis	0.00238	0.00358	CcSEcCtD
Apraclonidine—Pain—Niacin—atherosclerosis	0.00237	0.00357	CcSEcCtD
Apraclonidine—Fatigue—Pravastatin—atherosclerosis	0.00235	0.00355	CcSEcCtD
Apraclonidine—Constipation—Pravastatin—atherosclerosis	0.00233	0.00352	CcSEcCtD
Apraclonidine—Pain—Pravastatin—atherosclerosis	0.00233	0.00352	CcSEcCtD
Apraclonidine—Hypersensitivity—Ezetimibe—atherosclerosis	0.00233	0.00352	CcSEcCtD
Apraclonidine—Asthenia—Lovastatin—atherosclerosis	0.00232	0.00349	CcSEcCtD
Apraclonidine—Pruritus—Lovastatin—atherosclerosis	0.00228	0.00344	CcSEcCtD
Apraclonidine—Asthenia—Ezetimibe—atherosclerosis	0.00227	0.00342	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Niacin—atherosclerosis	0.00227	0.00342	CcSEcCtD
Apraclonidine—Nausea—Rosuvastatin—atherosclerosis	0.00226	0.00341	CcSEcCtD
Apraclonidine—Feeling abnormal—Pravastatin—atherosclerosis	0.00225	0.00339	CcSEcCtD
Apraclonidine—Pruritus—Ezetimibe—atherosclerosis	0.00224	0.00338	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00223	0.00336	CcSEcCtD
Apraclonidine—Hypersensitivity—Simvastatin—atherosclerosis	0.00222	0.00335	CcSEcCtD
Apraclonidine—Diarrhoea—Lovastatin—atherosclerosis	0.00221	0.00333	CcSEcCtD
Apraclonidine—Abdominal pain—Niacin—atherosclerosis	0.00219	0.0033	CcSEcCtD
Apraclonidine—Asthenia—Simvastatin—atherosclerosis	0.00217	0.00326	CcSEcCtD
Apraclonidine—Diarrhoea—Ezetimibe—atherosclerosis	0.00217	0.00326	CcSEcCtD
Apraclonidine—Abdominal pain—Pravastatin—atherosclerosis	0.00216	0.00325	CcSEcCtD
Apraclonidine—Pruritus—Simvastatin—atherosclerosis	0.00214	0.00322	CcSEcCtD
Apraclonidine—Dizziness—Lovastatin—atherosclerosis	0.00213	0.00322	CcSEcCtD
Apraclonidine—Dizziness—Ezetimibe—atherosclerosis	0.00209	0.00316	CcSEcCtD
Apraclonidine—Diarrhoea—Simvastatin—atherosclerosis	0.00206	0.00311	CcSEcCtD
Apraclonidine—Vomiting—Lovastatin—atherosclerosis	0.00205	0.00309	CcSEcCtD
Apraclonidine—Hypersensitivity—Niacin—atherosclerosis	0.00204	0.00308	CcSEcCtD
Apraclonidine—Dermatitis—Lovastatin—atherosclerosis	0.00203	0.00306	CcSEcCtD
Apraclonidine—Headache—Lovastatin—atherosclerosis	0.00202	0.00305	CcSEcCtD
Apraclonidine—Vomiting—Ezetimibe—atherosclerosis	0.00201	0.00303	CcSEcCtD
Apraclonidine—Hypersensitivity—Pravastatin—atherosclerosis	0.00201	0.00303	CcSEcCtD
Apraclonidine—Dizziness—Simvastatin—atherosclerosis	0.002	0.00301	CcSEcCtD
Apraclonidine—Dermatitis—Ezetimibe—atherosclerosis	0.00199	0.00301	CcSEcCtD
Apraclonidine—Asthenia—Niacin—atherosclerosis	0.00199	0.003	CcSEcCtD
Apraclonidine—Headache—Ezetimibe—atherosclerosis	0.00198	0.00299	CcSEcCtD
Apraclonidine—Pruritus—Niacin—atherosclerosis	0.00196	0.00296	CcSEcCtD
Apraclonidine—Asthenia—Pravastatin—atherosclerosis	0.00196	0.00295	CcSEcCtD
Apraclonidine—Pruritus—Pravastatin—atherosclerosis	0.00193	0.00291	CcSEcCtD
Apraclonidine—Vomiting—Simvastatin—atherosclerosis	0.00192	0.00289	CcSEcCtD
Apraclonidine—Nausea—Lovastatin—atherosclerosis	0.00192	0.00289	CcSEcCtD
Apraclonidine—Dermatitis—Simvastatin—atherosclerosis	0.0019	0.00287	CcSEcCtD
Apraclonidine—Diarrhoea—Niacin—atherosclerosis	0.0019	0.00286	CcSEcCtD
Apraclonidine—Headache—Simvastatin—atherosclerosis	0.00189	0.00285	CcSEcCtD
Apraclonidine—Nausea—Ezetimibe—atherosclerosis	0.00188	0.00283	CcSEcCtD
Apraclonidine—Diarrhoea—Pravastatin—atherosclerosis	0.00187	0.00281	CcSEcCtD
Apraclonidine—Dizziness—Niacin—atherosclerosis	0.00183	0.00276	CcSEcCtD
Apraclonidine—Dizziness—Pravastatin—atherosclerosis	0.0018	0.00272	CcSEcCtD
Apraclonidine—Nausea—Simvastatin—atherosclerosis	0.00179	0.0027	CcSEcCtD
Apraclonidine—Vomiting—Niacin—atherosclerosis	0.00176	0.00266	CcSEcCtD
Apraclonidine—Dermatitis—Niacin—atherosclerosis	0.00175	0.00263	CcSEcCtD
Apraclonidine—Headache—Niacin—atherosclerosis	0.00174	0.00262	CcSEcCtD
Apraclonidine—Vomiting—Pravastatin—atherosclerosis	0.00173	0.00262	CcSEcCtD
Apraclonidine—Dermatitis—Pravastatin—atherosclerosis	0.00172	0.00259	CcSEcCtD
Apraclonidine—Headache—Pravastatin—atherosclerosis	0.00171	0.00258	CcSEcCtD
Apraclonidine—Nausea—Niacin—atherosclerosis	0.00165	0.00248	CcSEcCtD
Apraclonidine—Nausea—Pravastatin—atherosclerosis	0.00162	0.00244	CcSEcCtD
Apraclonidine—ADRA2A—Signaling Pathways—VWF—atherosclerosis	0.000116	0.000345	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NCF1—atherosclerosis	0.000115	0.000343	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOC3—atherosclerosis	0.000115	0.000343	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LDLR—atherosclerosis	0.000115	0.000341	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—TGFB1—atherosclerosis	0.000114	0.00034	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KNG1—atherosclerosis	0.000114	0.000339	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—HMOX1—atherosclerosis	0.000114	0.000339	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AGTR1—atherosclerosis	0.000114	0.000337	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AGT—atherosclerosis	0.000113	0.000336	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—F2—atherosclerosis	0.000112	0.000334	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL3—atherosclerosis	0.000112	0.000333	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PIK3CG—atherosclerosis	0.000112	0.000332	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CCL2—atherosclerosis	0.000111	0.000331	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PLG—atherosclerosis	0.000111	0.000329	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AGT—atherosclerosis	0.00011	0.000328	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—MAPK3—atherosclerosis	0.00011	0.000327	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—APOB—atherosclerosis	0.000109	0.000324	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCR2—atherosclerosis	0.000109	0.000324	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EDNRA—atherosclerosis	0.000109	0.000324	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CYBA—atherosclerosis	0.000109	0.000322	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ABCA1—atherosclerosis	0.000108	0.000321	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000108	0.000319	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NCF1—atherosclerosis	0.000107	0.000319	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—TGFB1—atherosclerosis	0.000107	0.000317	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KNG1—atherosclerosis	0.000107	0.000317	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GSTM1—atherosclerosis	0.000106	0.000316	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GHRL—atherosclerosis	0.000106	0.000316	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PLAT—atherosclerosis	0.000106	0.000316	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PARP1—atherosclerosis	0.000106	0.000316	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AGTR1—atherosclerosis	0.000106	0.000315	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SOCS3—atherosclerosis	0.000105	0.000311	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—F2—atherosclerosis	0.000104	0.00031	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—LPL—atherosclerosis	0.000104	0.00031	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CCL2—atherosclerosis	0.000104	0.000309	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PLG—atherosclerosis	0.000103	0.000307	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AGT—atherosclerosis	0.000103	0.000305	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—F2—atherosclerosis	0.000102	0.000303	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GPX1—atherosclerosis	0.000102	0.000302	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCR2—atherosclerosis	0.000101	0.000301	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EDNRA—atherosclerosis	0.000101	0.000301	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MMP3—atherosclerosis	0.000101	0.000301	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CYBA—atherosclerosis	0.000101	0.0003	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF2—atherosclerosis	0.000101	0.000299	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3CG—atherosclerosis	9.99e-05	0.000297	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CD36—atherosclerosis	9.91e-05	0.000294	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PLAT—atherosclerosis	9.87e-05	0.000293	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GHRL—atherosclerosis	9.87e-05	0.000293	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PARP1—atherosclerosis	9.87e-05	0.000293	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SOCS3—atherosclerosis	9.79e-05	0.000291	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOB—atherosclerosis	9.78e-05	0.00029	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CG—atherosclerosis	9.76e-05	0.00029	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CXCL8—atherosclerosis	9.7e-05	0.000288	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EDN1—atherosclerosis	9.62e-05	0.000286	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCL5—atherosclerosis	9.55e-05	0.000284	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—F2—atherosclerosis	9.48e-05	0.000282	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—VEGFA—atherosclerosis	9.45e-05	0.000281	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MMP3—atherosclerosis	9.45e-05	0.000281	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF2—atherosclerosis	9.41e-05	0.000279	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—MTHFR—atherosclerosis	9.39e-05	0.000279	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—LPL—atherosclerosis	9.34e-05	0.000277	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KNG1—atherosclerosis	9.33e-05	0.000277	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AGTR1—atherosclerosis	9.27e-05	0.000275	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—HMOX1—atherosclerosis	9.26e-05	0.000275	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PPARA—atherosclerosis	9.21e-05	0.000274	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOB—atherosclerosis	9.13e-05	0.000271	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCL2—atherosclerosis	9.09e-05	0.00027	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PRKCG—atherosclerosis	9.08e-05	0.00027	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CG—atherosclerosis	9.07e-05	0.000269	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CXCL8—atherosclerosis	9.06e-05	0.000269	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PLG—atherosclerosis	9.03e-05	0.000268	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EDN1—atherosclerosis	8.99e-05	0.000267	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—MAPK3—atherosclerosis	8.94e-05	0.000266	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AGT—atherosclerosis	8.92e-05	0.000265	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCL5—atherosclerosis	8.92e-05	0.000265	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOB—atherosclerosis	8.87e-05	0.000264	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SPP1—atherosclerosis	8.84e-05	0.000263	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CXCL8—atherosclerosis	8.81e-05	0.000262	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—APOE—atherosclerosis	8.74e-05	0.00026	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—LPL—atherosclerosis	8.72e-05	0.000259	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TGFB1—atherosclerosis	8.68e-05	0.000258	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KNG1—atherosclerosis	8.66e-05	0.000257	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CAV1—atherosclerosis	8.66e-05	0.000257	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—APOA1—atherosclerosis	8.64e-05	0.000257	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GSTM1—atherosclerosis	8.63e-05	0.000256	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AGTR1—atherosclerosis	8.61e-05	0.000256	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SOCS3—atherosclerosis	8.56e-05	0.000254	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PRKCG—atherosclerosis	8.48e-05	0.000252	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—LPL—atherosclerosis	8.47e-05	0.000252	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCL2—atherosclerosis	8.45e-05	0.000251	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PLG—atherosclerosis	8.39e-05	0.000249	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GPX1—atherosclerosis	8.27e-05	0.000246	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MMP3—atherosclerosis	8.26e-05	0.000245	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SPP1—atherosclerosis	8.26e-05	0.000245	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF2—atherosclerosis	8.23e-05	0.000244	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CXCL8—atherosclerosis	8.22e-05	0.000244	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PDGFB—atherosclerosis	8.18e-05	0.000243	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CD36—atherosclerosis	8.05e-05	0.000239	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AGT—atherosclerosis	7.99e-05	0.000237	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOB—atherosclerosis	7.99e-05	0.000237	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—AKT1—atherosclerosis	7.95e-05	0.000236	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SOCS3—atherosclerosis	7.95e-05	0.000236	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CXCL8—atherosclerosis	7.92e-05	0.000235	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CG—atherosclerosis	7.89e-05	0.000234	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EDN1—atherosclerosis	7.86e-05	0.000233	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOE—atherosclerosis	7.83e-05	0.000232	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—LEP—atherosclerosis	7.83e-05	0.000232	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL5—atherosclerosis	7.8e-05	0.000232	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CAV1—atherosclerosis	7.76e-05	0.00023	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOA1—atherosclerosis	7.74e-05	0.00023	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MMP3—atherosclerosis	7.68e-05	0.000228	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PDGFB—atherosclerosis	7.64e-05	0.000227	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF2—atherosclerosis	7.64e-05	0.000227	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—MTHFR—atherosclerosis	7.63e-05	0.000227	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LPL—atherosclerosis	7.63e-05	0.000226	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PPARG—atherosclerosis	7.62e-05	0.000226	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPARA—atherosclerosis	7.48e-05	0.000222	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ESR1—atherosclerosis	7.47e-05	0.000222	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—INS—atherosclerosis	7.47e-05	0.000222	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AGT—atherosclerosis	7.46e-05	0.000222	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—AKT1—atherosclerosis	7.43e-05	0.000221	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOB—atherosclerosis	7.42e-05	0.00022	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PRKCG—atherosclerosis	7.41e-05	0.00022	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—F2—atherosclerosis	7.38e-05	0.000219	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCL8—atherosclerosis	7.36e-05	0.000218	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—LEP—atherosclerosis	7.31e-05	0.000217	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOE—atherosclerosis	7.31e-05	0.000217	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EDN1—atherosclerosis	7.3e-05	0.000217	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AGT—atherosclerosis	7.25e-05	0.000215	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL5—atherosclerosis	7.25e-05	0.000215	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CAV1—atherosclerosis	7.24e-05	0.000215	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOA1—atherosclerosis	7.23e-05	0.000215	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SPP1—atherosclerosis	7.22e-05	0.000214	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCL8—atherosclerosis	7.19e-05	0.000214	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOE—atherosclerosis	7.1e-05	0.000211	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LPL—atherosclerosis	7.08e-05	0.00021	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CG—atherosclerosis	7.06e-05	0.00021	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CAV1—atherosclerosis	7.04e-05	0.000209	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOA1—atherosclerosis	7.02e-05	0.000209	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ESR1—atherosclerosis	6.98e-05	0.000207	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—F2—atherosclerosis	6.89e-05	0.000205	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRKCG—atherosclerosis	6.89e-05	0.000205	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALB—atherosclerosis	6.85e-05	0.000203	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—MAPK3—atherosclerosis	6.77e-05	0.000201	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SPP1—atherosclerosis	6.71e-05	0.000199	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—INS—atherosclerosis	6.69e-05	0.000199	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PDGFB—atherosclerosis	6.68e-05	0.000198	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCL8—atherosclerosis	6.68e-05	0.000198	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CG—atherosclerosis	6.6e-05	0.000196	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCL2—atherosclerosis	6.58e-05	0.000195	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—NOS3—atherosclerosis	6.55e-05	0.000195	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AGT—atherosclerosis	6.52e-05	0.000194	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF1—atherosclerosis	6.47e-05	0.000192	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CG—atherosclerosis	6.41e-05	0.00019	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOE—atherosclerosis	6.39e-05	0.00019	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LEP—atherosclerosis	6.39e-05	0.00019	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CAV1—atherosclerosis	6.33e-05	0.000188	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—MAPK3—atherosclerosis	6.32e-05	0.000188	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOA1—atherosclerosis	6.32e-05	0.000188	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—INS—atherosclerosis	6.25e-05	0.000186	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PDGFB—atherosclerosis	6.21e-05	0.000184	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPARG—atherosclerosis	6.19e-05	0.000184	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCL2—atherosclerosis	6.15e-05	0.000183	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SERPINE1—atherosclerosis	6.14e-05	0.000182	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ESR1—atherosclerosis	6.1e-05	0.000181	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—INS—atherosclerosis	6.07e-05	0.00018	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AGT—atherosclerosis	6.06e-05	0.00018	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF1—atherosclerosis	6.04e-05	0.000179	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—AKT1—atherosclerosis	6.03e-05	0.000179	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—F2—atherosclerosis	6.03e-05	0.000179	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTGS2—atherosclerosis	5.99e-05	0.000178	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LEP—atherosclerosis	5.94e-05	0.000176	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOE—atherosclerosis	5.94e-05	0.000176	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CAV1—atherosclerosis	5.88e-05	0.000175	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOA1—atherosclerosis	5.87e-05	0.000174	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOS3—atherosclerosis	5.86e-05	0.000174	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CG—atherosclerosis	5.77e-05	0.000171	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SERPINE1—atherosclerosis	5.74e-05	0.00017	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	5.67e-05	0.000168	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—F2—atherosclerosis	5.6e-05	0.000166	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALB—atherosclerosis	5.56e-05	0.000165	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—MAPK3—atherosclerosis	5.52e-05	0.000164	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOS3—atherosclerosis	5.48e-05	0.000163	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—INS—atherosclerosis	5.46e-05	0.000162	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	5.37e-05	0.00016	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	5.36e-05	0.000159	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—NOS3—atherosclerosis	5.32e-05	0.000158	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	5.28e-05	0.000157	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCL8—atherosclerosis	5.2e-05	0.000154	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	5.13e-05	0.000152	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—INS—atherosclerosis	5.07e-05	0.000151	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AKT1—atherosclerosis	5.02e-05	0.000149	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	5.02e-05	0.000149	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	4.99e-05	0.000148	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—atherosclerosis	4.95e-05	0.000147	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	4.91e-05	0.000146	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS2—atherosclerosis	4.87e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCL8—atherosclerosis	4.86e-05	0.000144	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	4.79e-05	0.000142	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MMP9—atherosclerosis	4.7e-05	0.00014	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AKT1—atherosclerosis	4.69e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	4.66e-05	0.000138	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NFKB1—atherosclerosis	4.65e-05	0.000138	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—atherosclerosis	4.62e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK8—atherosclerosis	4.58e-05	0.000136	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AKT1—atherosclerosis	4.56e-05	0.000136	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	4.45e-05	0.000132	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MMP9—atherosclerosis	4.39e-05	0.000131	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NFKB1—atherosclerosis	4.35e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK8—atherosclerosis	4.27e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AKT1—atherosclerosis	4.26e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	4.25e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—VEGFA—atherosclerosis	4.22e-05	0.000125	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—STAT3—atherosclerosis	4.18e-05	0.000124	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	4.1e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	4.04e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK3—atherosclerosis	4e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	3.95e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—VEGFA—atherosclerosis	3.95e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—STAT3—atherosclerosis	3.91e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TGFB1—atherosclerosis	3.88e-05	0.000115	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	3.84e-05	0.000114	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	3.81e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	3.8e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	3.75e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	3.74e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK3—atherosclerosis	3.73e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	3.73e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TGFB1—atherosclerosis	3.62e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	3.57e-05	0.000106	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	3.53e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	3.47e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	3.46e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	3.45e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	3.42e-05	0.000101	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	3.26e-05	9.69e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	3.21e-05	9.52e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	3.17e-05	9.43e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	3.17e-05	9.4e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	3.03e-05	9.01e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AKT1—atherosclerosis	3.01e-05	8.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	2.94e-05	8.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—atherosclerosis	2.92e-05	8.68e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—atherosclerosis	2.73e-05	8.11e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT1—atherosclerosis	2.7e-05	8.01e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT1—atherosclerosis	2.52e-05	7.48e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AKT1—atherosclerosis	2.45e-05	7.26e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—atherosclerosis	2.39e-05	7.09e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—atherosclerosis	2.22e-05	6.58e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	2.2e-05	6.54e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	2.05e-05	6.07e-05	CbGpPWpGaD
